Clinical trials: Cardiac Decompensation
Heart Failure; With Decompensation
Biomarker Guided Discharge of Heart Failure Patients
This is a multi-centre, single blind, randomized study. Patients admitted to hospital with acute decompensated heart failure will be randomized to biomarker guided discharge algorithm vs usual care in a 2:1 ratio.
- Trial name
- RADAR (NCT03103932)
- Testing
- Biomarker guided discharge algorithm
- Where
- Canada
- Volunteers
- 750 people
- Sponsor
- Ottawa Heart Institute Research Corporation
MASLD, Liver Cirrhosis, Alcoholic
Acquisition of Cardiac Function Parameters in MRI and Echocardiography in Patients With Ethyltoxic Liver Cirrhosis and Transjugular Intrahepatic Portosystemic Shunt (TIPSS) Placement
The aim of this clinical trial is to investigate the development of cardiac decompensation following transjugular intrahepatic portosystemic shunt (TIPSS) implantation in order to draw conclusions for future treatment methods or…
- Conditions
- MASLD, Liver Cirrhosis, Alcoholic, Cirrhosis of Liver, Heart Decompensation
- Trial name
- EVALUATION (NCT06814990)
- Testing
- Cardiac MRI, Blood samples, Echocardiography
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Stephanie Gräger
COVID-19, Long COVID
Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
We are conducting a research study at the VA hospital in Bedford, MA to learn more about how a multisensor rapid health assessment device, MouthLab, can help predict or anticipate future health complications in patients with…
- Trial name
- AIDI (NCT05713266)
- Testing
- MouthLabTM
- Where
- United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Edith Nourse Rogers Memorial Veterans Hospital
Heart Decompensation
Treating Congestive Heart Failure Using a Device to Remove Cholesterol
A pilot study to examine the effects of LDL-Apheresis on patients with Stage III Congestive Heart Failure. Study hypothesis: Decreased blood viscosity from receiving LDL-apheresis will decrease workload on the heart and improve…
- Trial name
- NCT00510601
- Testing
- Kaneka Liposorber
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Patrick Moriarty, MD, FACP, FACC
Heart Failure, Heart Failure, Systolic
Hemodynamic-GUIDEd Management of Heart Failure
The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for…
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II
- Trial name
- GUIDE-HF (NCT03387813)
- Testing
- CardioMEMS™ HF System
- Where
- 129 sites in United States, Canada
- Volunteers
- 2,358 people
- Sponsor
- Abbott Medical Devices
Heart Failure
Nanowear Heart Failure Management Multi-sensor Algorithm
The NanoSense study is a multi-center, prospective, non-randomized, observational, feasibility, non-significant risk study. The NanoSense study will enroll up to 500 subjects in up to 10 centers in order to collect data which…
- Trial name
- Nanosense (NCT03719079)
- Testing
- SimpleSENSE
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Nanowear Inc.
Heart Failure
Anticipation and Detection of Heart Failure Decompensation With Automatic Treatment of Informations
Heart failure (HF) is a serious chronic disease with frequent readmissions, some of which can be prevented by early action. The management of HF is complex: long, often difficult and costly.
- Trial name
- e-INCA (NCT02411279)
- Testing
- Equiped group with telemedicine systems
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Strasbourg, France
Chronic Heart Failure, Heart Decompensation
Early-start Exercise Training in Subacute Heart Failure
The purpose of this study is to evaluate the feasibility and the short-term effects of an early-start aerobic exercise training program on functional capacity, symptoms and neurohormonal activation in chronic heart failure…
- Trial name
- RE-START (NCT02051985)
- Testing
- Aerobic exercise training, Standard physical therapy
- Where
- 9 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione Salvatore Maugeri
Acute Heart Failure, Acute Decompensation of Chronic Heart Failure
Tezosentan in the Treatment of Acute Heart Failure
The randomized patients with acute heart failure will be stratified based on the presence or absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the first 30 minutes and 1 mg/h thereafter or…
- Conditions
- Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure
- Trial name
- VERITAS 2 (NCT00524433)
- Testing
- tezosentan
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 713 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Heart Failure, Congestive, Heart Decompensation
Registry for Acute Decompensated Heart Failure Patients Admitted to the ER
The purpose of this study is to collect data on the medical management of patients presenting to the Emergency Department who are treated for Acute Decompensated Heart Failure (ADHF) in a hospital setting that has incorporated a…
- Trial name
- NCT00364325
- Testing
- Acute Decompensated Heart Failure
- Volunteers
- 18,920 people
- Sponsor
- Scios, Inc.
Heart Failure, Congestive, Heart Decompensation
Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure
The study will evaluate the safety and efficacy of intravenous infusion of carperitide using pressure measurements inside the heart and great vessels and measuring carperitide concentration in the blood.
- Conditions
- Heart Failure, Congestive, Heart Decompensation, Left Ventricular Failure, Myocardiopathies
- Trial name
- NCT00259038
- Testing
- Carperitide
- Where
- 34 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- Daiichi Sankyo
Heart Failure, Acute Heart Failure
Protocol of Diuretics Use in Congestive Therapy in Heart Failure
The main objective of the study is to determine if a diuretic adaptation protocol in the decompensation of chronic heart failure is more effective but also safer than the current non-protocolized practice.
- Conditions
- Heart Failure, Acute Heart Failure, Chronic Heart Failure
- Trial name
- ProDUCT-HF (NCT03892148)
- Testing
- Furosemide, Hydrochlorothiazide
- Where
- 9 sites in France
- Volunteers
- 299 people
- Sponsor
- University Hospital, Clermont-Ferrand
Heart Failure; With Decompensation
Evaluation Of A Virtual Cardiology Program To Improve Outcomes After Acute Decompensated Heart Failure
The purpose of this study is to evaluate how safe and effective a remote, virtual, cardiology program is that provides heart failure education to patients, monitors for worsening heart failure, and quickly adjusts heart failure…
- Trial name
- ELEVATE-HF (NCT06592508)
- Testing
- Remote Virtual Cardiology Program
- Where
- 5 sites in United States
- Volunteers
- 73 people
- Sponsor
- Duke University
Heart Failure; With Decompensation
Danger Signs in Heart Failure- Effects of Video Education
Lack of recognition of HF danger signs and lack of understanding of how to control and minimize danger signs could lead to their escalation and prompt all-cause and HF-related health care resource utilization (HCRU).
- Trial name
- NCT03657459
- Testing
- Danger Signs of Heart Failure Videos
- Where
- 8 sites in United States
- Volunteers
- 746 people
- Sponsor
- The Cleveland Clinic
Heart Failure; With Decompensation
Heart Sounds Registry
To conduct a prospective, observational study to evaluate the non-interventional feasibility of using heart sounds measurements recorded by the LifeVest® Wearable Cardioverter Defibrillator (WCD) for monitoring clinical evidence…
- Trial name
- HEARIT-Reg (NCT03203629)
- Testing
- Wearable Cardioverter Defibrillator (WCD)
- Where
- 33 sites in United States, Austria and 2 more
- Volunteers
- 705 people
- Sponsor
- Zoll Medical Corporation
Heart Failure
Ambulatory Heart Failure Service Model Study
The aim of the study is to assess the efficacy of this new ambulatory service model in reducing heart failure hospitalization (HHF), improving clinical as well as functional outcomes of post-discharge patients with Heart Failure…
- Trial name
- REDUCE-HF (NCT05556031)
- Testing
- Standard care
- Where
- Hong Kong
- Volunteers
- 500 people
- Sponsor
- Chinese University of Hong Kong
Heart Failure (HF)
A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
This study is a prospective, open-label, single-arm intervention study in African-American/Black subjects with heart failure and reduced ejection fraction (HFrEF).
- Trial name
- NCT03456856
- Testing
- Ivabradine
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Amgen
Liver Dysfunction, Liver Insufficiency
An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function
This is an investigational study of experimental Medication BMS-986231 given to participants with weakened or damaged liver function.
- Conditions
- Liver Dysfunction, Liver Insufficiency, Hepatic Failure, Myocardial Failure
- Trial name
- NCT03515980
- Testing
- BMS-986231
- Where
- 4 sites in Hungary, Poland
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Heart Failure, Congestive, Heart Decompensation
A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood Vessels
The purpose of this safety study is to evaluate NATRECOR® hBNP (a recombinant form of the natural human peptide normally secreted by the heart in response to heart failure), in subjects with worsening congestive heart failure…
- Trial name
- NCT00271557
- Testing
- nesiritide
- Volunteers
- 305 people
- Sponsor
- Scios, Inc.
Heart Failure
Decompensation Detection Study
To gather data and analyze decompensation events.
- Trial name
- NCT00583089
- Volunteers
- 699 people
- Sponsor
- Boston Scientific Corporation